Activity Preview


FOCUS Quiz: Summer 2018 - Emerging Therapies in Psychiatry

Activity Type:

  • Journal CME

Release Date: 7/1/2018

Expiration Date: 12/31/2020

  • AMA PRA Category 1: 5
  • Participation: 5

Access Activity


Emerging Therapies in Psychiatry

FOCUS, APA's clinical review and continuing medical education journal, is designed as a personal study resource to help practicing psychiatrists keep abreast of significant advances in the field, with particular attention to clinical practice and incorporation of core competencies. The goal of FOCUS is the dissemination of up-to-date clinical information, facilitation of lifelong learning skills, maintenance of certification, and opportunity for self-assessment in order to improve patient care. Each issue, prepared by distinguished faculty who are recognized in their fields, provides up to date clinical information and incorporates a CME component. The material can be used effectively by establishing a regular schedule of study.


This activity is only available to 2018 Focus subscribers.

Don't have a subscription to 2018 Focus? Subscribe online or by phone at 1-800-368-5777.  

If you have questions about Focus subscriptions, please contact

Educational Objectives

As a result of this activity, participants will:

• review the theory behind ketamine and related medications for use in depression and the elements of the pharmacology of ketamine
• synthesize the findings and limitations of human studies and be aware of important risks and precautions
• review uses of virtual reality in clinical practice and other emerging therapies with clinical applications
• review developments in computer technologies for mental health

Target Audience

This program is one element of a lifelong learning program for psychiatrists and is an aid for psychiatrists and other clinicians participating in maintenance of certification.

Estimated Time to Complete

Estimated Duration: 5 hours
Begin Date: July 1, 2018
End Date: December 31, 2020

How to Earn Credit

In order to earn CME credit, participants should read through the material presented in the issue. After reading the materials, complete the CME quiz by answering multiple-choice questions with a single correct answer. A score of 60% or higher is required to receive credit. Retakes are available for the test. Review the rationales, complete the online course evaluation, and then claim and print your CME certificate. The APA provides a CME certificate of credit for physicians and a certificate of participation for non-physicians.


The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this journal-based CME activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Program Planners – Editor and Associate Editors and Guest Editors

Mark H. Rapaport, M.D., Editor of FOCUS, and Chairman and Chief of Psychiatric Services, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga. No financial relationships with commercial interests.

Dorothy Stubbe, M.D., Editor Communications Commentary, Associate Professor and Program Director, Yale University School of Medicine Child Study Center, New Haven, CT.- No financial relationships with commercial interests.

Laura Dunn, M.D., Co-Editor Ethics Column; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA; Dr. Dunn reports: Consultant: Otsuka America Pharmaceutical Inc.

Ian A. Cook, M.D., D.F.A.P.A. Guest Editor, Section Editor and Author Patient Management: is Chief Translational Innovation Officer for the Semel Institute for Neuroscience and Human Behavior, and is a Professor with the Department of Psychiatry and Biobehavioral Sciences of the David Geffen School of Medicine, and the Department of Bioengineering of the Henry Samueli School of Engineering and Applied Science at the University of California, Los Angeles. He is also with the Veterans Affairs Greater Los Angeles Healthcare System.  Dr. Cook reports that his active biomedical device patents are assigned to the University of California. In the last year, he has advised Arctica Health, Cerêve, and NeuroDetect, and UCLA has received research grant funding from NeoSync, Inc., for his work.  He has been granted stock options in NeuroSigma, the licensee of some of his inventions, and he currently is on-leave as its chief medical officer and senior vice president.

Boadie Dunlop, M.D.  Section Editor Applied Armamentarium, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia. Grant/Research: Axome, Assurex, Acadia, Janssen, NIMH, Takeda

FOCUS Author Affiliation and Disclosure Information

Whole-Body Heating: An Emerging Therapeutic Approach to Treatment of Major Depressive Disorder
Christopher Lowry, Ph.D., Michael Flux, M.S., Charles Raison, M.D.

Dr. Lowry is with the Department of Integrative Physiology and Center  for Neuroscience, University of Colorado, Boulder. Mr. Flux is with the   Department of Psychology and Neuroscience, University of Colorado, Boulder. Dr. Raison is with the School of Human Ecology, University of   Wisconsin. During the preparation of this article, Dr. Lowry was supported by a   grant from the National Institute of Mental Health (grant number   1R21MH116263); a grant from the U.S. Department of the Navy, Office of   Naval Research Multidisciplinary University Research Initiative (MURI;   grant number N00014-15-1-2809); a grant from the Department of   Veterans Affairs Office of Research and Development (VA-ORD) RR&D   Small Projects in Rehabilitation Research (SPiRE [I21]; grant number 1 I21   RX002232-01); a grant from the Colorado Clinical & Translational Sciences   Institute (CCTSI) Center for Neuroscience (grant number CNSTT-   15-145); a grant from the Colorado Department of Public Health and   Environment (CDPHE; grant number DCEED-3510); and a grant from   the Alfred P. Sloan Foundation (grant number G-2016-7077).   Dr. Lowry serves on the Scientific Advisory Board of Immodulon Therapeutics,  Ltd. Dr. Raison is director of Clinical and Translational Research  for Usona Institute Alkermes and Novartis.Mr. Flux reports no financial relationships with   commercial interests.

Digital Technologies in Psychiatry: Present and Future

Mathew E. Hirschtritt, M.D., M.P.H., and Thomas R. Insel, M.D.

Dr. Hirschtritt is with the Weill Institute for Neurosciences and Department   of Psychiatry, University of California, San Francisco. Dr. Insel is with Mindstrong Health, Palo Alto, CA

This work was funded in part by grant 5R25MH060482-17 from the National Institute of Mental Health (NIMH) to Dr. Hirschtritt.   NIMH funding had no involvement in the conception, drafting, review, or approval of the manuscript. Dr. Hirschtritt serves as a consultant to Carbon Health. Dr. Insel is an employee of Mindstrong Health and has equity interest in Alphabet, Apple, and Mindstrong Health. He serves on the boards of Mindstrong Health, Inscopix, Compass Pathways, and 7 Cups.     

Ethical Issues in Emerging Treatments for Neuropsychiatric Disorders

Paul P. Christopher, M.D.  Dr. Christopher is with the Department of Psychiatry and Human Behavior, Warren Alpert Medical School, Brown University, Providence, RI.   Dr. Christopher reports no financial relationships with commercial interests.

Experimental Therapies for Treatment-Resistant Depression

Manish K. Jha, M.D., Madhukar jjH. Trivedi, M.D., Center for Depression Research and Clinical Care, UT Southwestern Medical Center, Dallas, TX.

Dr. Jha, Grant Research: Acadia Pharmaceuticals and Janssen Research

Dr. Trivedi: Consultant:Alkeremes Inc., Akili Interactive, Navitor, Otsuka America Pharmaceutical Inc., Speaker's Bureau: Dartmouth College, Global Medical Education, University of Illinois Chicago, University of Ottawa, University of Texas Health Science Center at San Antonio. Grant/Research: (NIMH), (NIDA), National Center for Advancing Translational Sciences, Cancer Prevention and Research Institute of Texas, Patient-Centered Outcomes Research Institute (PCORI). Author Agreement: Janssen Asia Pacific, Oxford University Press;

Clinical Virtual Reality: Emerging Opportunities for Psychiatry

Albert “Skip” Rizzo, Ph.D., Director of Medical Virtual Reality Research, University of Southern California Institute for Creative Technologies. Sebastian Thomas Koenig, Ph.D., Director, Human Interface Technology Engineer Katana Simulations Pty Ltd, Adelaide, Australia. Thomas Talbot, M.D., Senior Research Scientist University of Southern California Institute for Creative Technologies

Dr. Rizzo reports no financial conflict relationships.

Dr. Koenig reports 100% ownership interest in Katana Simulations Pty Ltd, an Australian technology company developing clinical and educational virtual reality software.

Dr. Talbot, Consultant: Talbotics LLC - Consultant for National Board of Medical Examiners, U. Washington, U. Illinois Jump Simulation, Applied Research Associates, Charles River Analytics. Grant/Research: Multiple Grants from US Department of Defense for medical simulation. Other: Medical Mechanica LLC - virtual standardized patient technology licensing & development (owner)

Ketamine- A Review for Clinicians

Gerard Sanacora, M.D. Rachael Katz, M.D., Yale Department of Psychiatry Yale Interventional Psychiatry Service, Yale Psychiatric Hospital

Dr. Sanacora reports: Stock: Biohaven Pharmaceutical Company. Consultant: Allergan, Alkermes, Axsome Therapeutics, Biohaven Pharmaceuticals, Intra-Cellular Therapies, Janssen, Navitor Pharmaceuticals, Noven Pharmaceuticals, Sage Pharmaceuticals, Sofinnova, and Vistagen Therapeutics. Grant/Research: Merck and Janssen. Co-inventor on a patent, “Glutamate agents in the treatment of mental disorders”: Patent number: 8778979. Dr. Katz reports no relevant financial conflicts with commercial entities.

American Psychiatric Association staff involved in planning report no financial relationships with commercial interests:

Tristan Gorrindo M.D.,  Director, Division of Education, American Psychiatric Association

Kristen Moeller, Director of CME, Associate Director of FOCUS, American Psychiatric Association

FOCUS Editorial Board disclosure is published on the editorial board page of each issue.

Hardware/Software Requirements

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player. 

Optimal System Configuration

  • Flash Player: Adobe Flash Player 10.1+ 
  • Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
  • Operating System: Windows XP+ or Mac OS X 10.4+ 
  • Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera

Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact for questions about this course | Contact for technical assistance

Access Activity